文献速递胸部肿瘤支持与姑息治疗

扩大退伍军人临终关怀与晚期肺癌积极治疗及费用的关联

Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究评估13 085例新诊断IV期非小细胞肺癌退伍军人,比较退伍军人事务医疗中心临终关怀使用率最高与最低五分位年份的结局。结果显示高五分位组同时接受抗癌治疗的优势比为2.28,积极治疗优势比为0.66,ICU使用优势比为0.78,6个月费用每日估计低266美元,无生存差异。

要点

  • 高临终关怀使用组同时接受抗癌治疗的优势比为2.28(95%CI 1.67-3.31)。
  • 高临终关怀使用组积极治疗优势比为0.66(95%CI 0.53-0.81)。
  • 高临终关怀使用组6个月费用每日估计低266美元(95%CI -358至-164),无生存差异。

核心结论

  • 在未限制抗癌治疗可及性的前提下,增加临终关怀可及性与晚期肺癌退伍军人更少的积极治疗和显著更低的费用相关,同时仍提供抗癌治疗。

研究设计与样本

  • 采用改良倍差法研究设计,使用机构固定效应,比较临终关怀使用率相对高与低的年份间患者结局。
  • 研究纳入2006年至2012年间113个退伍军人事务医疗中心新诊断的13 085例IV期非小细胞肺癌退伍军人,每个中心每年至少5例。
  • 数据分析于2017年1月至2018年7月进行。
  • 利用退伍军人事务住院、门诊、药房索赔及类似医疗保险数据,构建医疗中心层面年度汇总的临终关怀使用、抗癌治疗及两者同时接受情况,将医疗中心年份按临终关怀可及性暴露分为五分位。

主要发现

  • 13 085例退伍军人中,12 858例(98%)为男性,10 531例(81%)为白人,5949例(46%)年龄大于65岁。
  • 位于临终关怀最高五分位(79%临终关怀使用者)的医疗中心,其非小细胞肺癌退伍军人接受临终关怀后同时接受抗癌治疗的可能性是最低五分位(55%临终关怀使用者)的2倍以上(调整优势比2.28;95%CI 1.67-3.31)。
  • 最高五分位组相对最低五分位组,诊断后6个月内接受积极治疗的调整优势比为0.66(95%CI 0.53-0.81),ICU使用的调整优势比为0.78(95%CI 0.62-0.99)。
  • 高五分位组相对低五分位组,6个月费用每日估计低266美元(95%CI -358至-164)。
  • 无生存差异。

关键数值与推荐

  • 积极治疗定义为30天内2次或以上住院、管饲、机械通气、ICU入住。
  • 主要结局为诊断后前6个月内接受积极治疗和总费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Medicare hospice beneficiaries discontinue disease-modifying treatments because the hospice benefit limits access. While veterans have concurrent access to hospice care and Veterans Affairs (VA) Medical Center (VAMC)-provided treatments, the association of this with changes in treatment and costs of veterans' end-of-life care is unknown. OBJECTIVE: To determine whether increasing availability of hospice care, without restrictions on disease-modifying treatments, is associated with reduced aggressive treatments and medical care costs at the end of life. DESIGN, SETTING, AND PARTICIPANTS: A modified difference-in-differences study design, using facility fixed effects, compared patient outcomes during years with relatively high vs lower hospice use. This study evaluated 13 085 veterans newly diagnosed with stage IV non-small cell lung cancer (NSCLC) from 113 VAMCs with a minimum of 5 veterans diagnosed with stage IV NSCLC per year, between 2006 and 2012. Data analyses were conducted between January 2017 and July 2018. EXPOSURES: Using VA inpatient, outpatient, pharmacy claims, and similar Medicare data, we created VAMC-level annual aggregates of all patients who died of cancer for hospice use, cancer treatment, and/or concurrent receipt of both in the last month of life, dividing all VAMC years into quintiles of exposure to hospice availability. MAIN OUTCOMES AND MEASURES: Receipt of aggressive treatments (2 or more hospital admissions within 30 days, tube feeding, mechanical ventilation, intensive care unit [ICU] admission) and total costs in the first 6 months after diagnosis. RESULTS: Of the 13 085 veterans included in the study, 12 858 (98%) were men; 10 531 (81%) were white, and 5949 (46%) were older than 65 years. Veterans with NSCLC treated in a VAMC in the top hospice quintile (79% hospice users), relative to the bottom quintile (55% hospice users), were more than twice as likely to have concurrent cancer treatment after initiating hospice care (adjusted odds ratio [AOR], 2.28; 95% CI, 1.67-3.31). Nonetheless, for veterans with NSCLC seen in VAMCs in the top hospice quintile, the AOR of receiving aggressive treatment in the 6 months after diagnosis was 0.66 (95% CI, 0.53-0.81), and the AOR of ICU use was 0.78 (95% CI, 0.62-0.99) relative to patients seen in VAMCs in the bottom hospice quintile. The 6-month costs were lower by an estimated $266 (95% CI, -$358 to -$164) per day for the high-quintile group vs the low-quintile group. There was no survival difference. CONCLUSIONS AND RELEVANCE: Increasing the availability of hospice care without restricting treatment access for veterans with advanced lung cancer was associated with less aggressive medical treatment and significantly lower costs while still providing cancer treatment.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mor V, Wagner TH, Levy C, et al. Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer. JAMA Oncol. 2019. PMID: 30920603. doi:10.1001/jamaoncol.2019.0081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。